Lay Line Genomics re-launches AntiTrkA project for the treatment of chronic pain
(Thomson Reuters ONE) -
(Rome, Italy, 8 March 2010) - Lay Line Genomics SpA (LLG,
www.laylinegenomics.com
the termination of the exclusive license agreement with BioXell SpA all rights
to the humanized antiTrkA monoclonal antibody named BXL1H5 are now back in the
full availability of LLG.
"BioXell advanced the development of the therapeutic antibody in the
pre-clinical stages, reaching relevant results in the characterization of the
product, in in-vivo tests and filing new Intellectual Property, so making
stronger an already very solid package of patents" - declared Ennio Esposito,
Sole Administrator of LLG, continuing with - "Based on those achievements as
well as from an important positive outcome of the appeal of LLG's base patent at
EPO , LLG will now take-over the work on BXL1H5. We are very excited about the
opportunity to re-launch this project which offers enormous potential from an
industrial point of view. The NGF/TrkA mechanism for the treatment of chronic
and inflammatory pain has always been a high priority topic in our agenda:
this is now well recognized also in the market, placing LLG in a uniquely strong
position in the booming field of therapeutic antibodies for chronic pain".
While carefully evaluating all the available strategic options, to rapidly
develop the project into clinical development, Lay Line Genomics has already
planned a set of additional tests with the antibody, including testing it on a
knock-in a transgenic mouse model with humanTrkA, so to add new data to the
existing package and to improve its competitive and strategic positioning.
About Lay Line Genomics
Lay Line Genomics was founded in 2001 as a spin-off of the International School
for Advanced Studies (SISSA, Trieste-Italy), with the mission to discover and
develop innovative biopharmaceuticals for the treatment of neurological
diseases.
The company had a period of strong growth in Research and Development, resulting
in a wide portfolio of patents and specific know-how/tools, currently mainly
applied by other companies through sale or license agreements. LLG is
concentrated in managing the company's assets, supporting its Partners
(Pharmaceuticals and Biotech companies) in the development of the sold/licensed
programs.
About Lay Line Genomics' Pain Program
Thanks to a unique know-how and target platform around Nerve Growth Factor (NGF)
and its receptor TrkA, crucial targets for chronic pain, Lay Line Genomics
developed in the years a wide program in the Pain field, leading to a strong
specific knowledge, IP position and full FTO in this area of activity.
Chronic and inflammatory pain encompasses a diverse set of poorly
treated/untreated pathological states. There is the need for a new generation of
drugs that target both the neuropathic and the inflammatory components of
chronic pain and the NGF/TrkA system identifies a new class of targets, well
validated in humans, for the development of new treatments.
LLG discovered and developed in parallel 2 humanized antibodies, targeting
respectively the ligand NGF and its receptor TrkA, the only player in the whole
pharmaceutical industry to have developed humanized antibodies targeting both
sides of the NGF/TrkA system. The antiNGF program was assigned to PanGenetics BV
in 2007, developed to the clinical phase and recently acquired by Abbott (see
www.pangenetics.com
exclusively licensed to Bioxell at the beginning of 2006: after termination of
the license with BioXell, the antiTrkA program is back in the hands of its
originators. With a dominant IP position and a strong scientific and know how
backing, both in the biology of the NGF/TrkA target and in the recombinant
antibody fields.
Source: Lay Line Genomics SPA, March 8, 2010
For further information, please contact:
Ennio Esposito
Tel: +39 06 55269979
e.esposito(at)laylinegenomics.com
[HUG#1391342]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2010 - 06:01 Uhr
Sprache: Deutsch
News-ID 1010959
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Roma
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 66 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lay Line Genomics re-launches AntiTrkA project for the treatment of chronic pain
"
steht unter der journalistisch-redaktionellen Verantwortung von
Lay Line Genomics S.p.A. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
